You just read:

Almirall and Athenex Announce Positive Topline Results from Two Phase III Studies of KX2-391 Ointment 1% Featured in Late Breaker Program at the 2019 American Academy of Dermatology Annual Meeting

News provided by

Almirall

Mar 04, 2019, 13:35 ET